Bio Nebraska and Bristol Myers Squibb host CAR T Cell Therapy event

Bio Nebraska partnered with member Bristol Myers Squibb to host a Lunch and Learn for Nebraska state senators and their staff about CAR T Cell Therapy, an innovative, next-generation cancer treatment.

Today, we partnered with Bristol Myers Squibb to host a Personalized Medicine and CAR T Cell Therapy Lunch and Learn for Nebraska state senators and their staff. Dr. Mathew Lunning, Associate Vice Chair of Research at the University of Nebraska Medical Center, and Jennifer Herring, Head Executive Director for Cellular Therapies at Bristol Myers Squibb, talked about how CAR T is an extraordinary and innovative cancer treatment that engineers a patient’s own cells to hunt and attack cancer cells and that it is a powerful tool for treating advanced forms of cancer and bringing hope to patients and families.

Thank you to our presenters for sharing information about this next-generation treatment for cancer and thank you to everyone who attended today’s event to learn more about CAR T Cell Therapy.   

Pictured from left: Jennifer Herring, Bristol Myers Squibb; Rob Owen, Bio Nebraska; Dr. Matthew Lunning, University of Nebraska Medical Center; Genevieve Plumadore, Bristol Myers Squibb.
Genevieve Plumadore, Bristol Myers Squibb, introduces Lunch and Learn speakers.